95 results
Page 3 of 5
8-K
EX-99.1
hbq2x
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.2
oz8qt rb2pf33eogd
19 May 21
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
qb9s0fek8yr9
19 May 21
Regulation FD Disclosure
5:00pm
S-3ASR
EX-1.2
sqoteut4nk0d3
2 Apr 21
Automatic shelf registration
4:59pm
S-3ASR
g4m4db bnh86je286
2 Apr 21
Automatic shelf registration
4:59pm
8-K
EX-1.1
r6k dfyygd7
9 Dec 20
Entry into a Material Definitive Agreement
4:38pm
424B5
yml bwpyy
9 Dec 20
Prospectus supplement for primary offering
4:02pm
424B5
aqiyhuvdg 101yc7s
7 Dec 20
Prospectus supplement for primary offering
4:10pm
8-K
opx5tmsc0e93
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
doj8ntroj6cqpqv
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
EX-99.1
4fth ukn6
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.2
022kcw4qitlvhw0i6fa
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
t0x xjfyq
9 Sep 20
Other Events
5:23pm
8-K
EX-99.2
7uyoab79i2908rb3 ka
9 Sep 20
Other Events
5:23pm